ScholarLens Back to search
2013•Medical Innovation of ChinaRequires access

A Clinical Controlled Study of Medilac-s and Mosapride Citrate Tablets in Constipation-predominant Irritable Bowel Syndrome

Huanle Zhang

Open publisher page 0 citations

Abstract

Objective:To explore the effect of Medilac-s(live combined bacillus subtilis and enterococcus faeciumenteric-coated capsule) combined with mosapride citrate tablets for the treatment of constipation-predominant irritable bowel syndrome(IBS). Method:IBS patients were randomly divided into 2 groups,the treatment group received Medilac-s 500 mg 3 times and mosapride citrate tablets 5 mg 3 times daily for 8 weeks. The control group received oryzanol tablets 20 mg 3 times a day for 8 weeks,Medilac-s 500 mg 3 times daily for 8 weeks. Result:The total efficiency rate of treatment group was 85.71%,and control group was 61.22%(P 0.05). Conclusion:Medilac-s combined with mosapride citrate tablets has better effect in the treatment of constipation-predominant irritable bowel syndrome.

About this research paper

What this paper is about

Objective:To explore the effect of Medilac-s(live combined bacillus subtilis and enterococcus faeciumenteric-coated capsule) combined with mosapride citrate tablets for the treatment of constipation-predominant irritable bowel syndrome(IBS). Method:IBS patients were randomly divided into 2 groups,the treatment group received Medilac-s 500 mg 3 times and mosapride citrate tablets 5 mg 3 times daily for 8 weeks. The control group received oryzanol tablets 20 mg 3 times a day for 8 weeks,Medilac-s 500 mg 3 times daily for 8 weeks. Result:The total efficiency rate of treatment group was 85.71%,and control group was 61.22%(P 0.05). Conclusion:Medilac-s combined with mosapride citrate tablets has better effect in the treatment of constipation-predominant irritable bowel syndrome.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To explore the effect of Medilac-s(live combined bacillus subtilis and enterococcus faeciumenteric-coated capsule) combined with mosapride citrate tablets for the treatment of constipation-predominant irritable bowel syndrome(IBS). Method:IBS patients were randomly divided into 2 groups,the treatment group received Medilac-s 500 mg 3 times and mosapride citrate tablets 5 mg 3 times daily for 8 weeks. The control group received oryzanol tablets 20 mg 3 times a day for 8 weeks,Medilac-s 500 mg 3 times daily for 8 weeks. Result:The total efficiency rate of treatment group was 85.71%,and control group was 61.22%(P 0.05). Conclusion:Medilac-s combined with mosapride citrate tablets has better effect in the treatment of constipation-predominant irritable bowel syndrome.

Key concepts: Medicine, Mosapride, Irritable bowel syndrome, Constipation, Gastroenterology, Internal medicine, Capsule, Biology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A Clinical Controlled Study of Medilac-s and Mosapride Citrate Tablets in Constipation-predominant Irritable Bowel Syndrome — Research Paper | ScholarLens